your market intelligence analyst
Search Results
381 results
Your search is now limited to «SGLT-2 Inhibitor» expert search.
FeedNavigator (EU) 08/25/2019 02:22
However, adverse events associated with SGLT2 inhibitors include genital mycotic infections, urinary tract infection, hypoglycemia, diabetic ketoacidosis, hypotension, acute kidney injury, fractures, and amputations [11.
More from FeedNavigator (EU):
Healio News 08/24/2019 08:00
Cardiology Today and Healio have compiled a list of the top 5 articles from the American Society for Preventative Cardiology’s Congress on CVD Prevention, held July 19 to 21 in San Antonio. VIDEO: Sex differences, barriers persist for women with heart disease In this video exclusive, Martha Gulati, MD, MS, FACC, FAHA, division chief of cardiology at the University of Arizona College of Medicine – Phoenix, physician executive director for Banner University Medicine Heart Institute and editor in chief of ACC’s CardioSmart, discusses the importance of considering.
More from Healio News:
Bio-Medicine.Org 08/23/2019 05:43
PENSACOLA, Fla. (PRWEB) August 23, 2019 The West Virginia Association of Optometric Physicians (WVAOP) announces a strategic partnership with the West Virginia Eye Collaborative. This partnership will be managed by Coherent Eye Care. With a keen focus on improving quality, value, and acces...
More from Bio-Medicine.Org:
Lancet 08/22/2019 19:13
Ischaemic heart disease has a multifactorial aetiology and can be prevented from developing in populations primordially, and in individuals at high risk by primary prevention. The primordial approach focuses on social determinants of health in populations: political, economic, and social factors, principally unplanned urbanisation, illiteracy, poverty, and working and living conditions. Implementation of the UN Sustainable Development Goals can lead to major improvements in cardiovascular health, and adequate health-care financing and universal health care are important for achieving these goals.
More from Lancet:
In this review, the clinical efficacy and safety of empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor in T1D, is described based on a review of phase 2 and 3 studies to date.
More from International Journal of COPD:
Business Wire 08/21/2019 19:01
SGLT2 inhibitors work by inhibiting SGLT2, which promotes the loss of glucose via the urine, lowering blood glucose levels in adults with T2DM.
More from Business Wire: 08/21/2019 03:46
Latest Research on “Global Diabetes Drugs Market 2019: Rising Industry Forecast Covering Growth Tendencies and Developments Until 2029.“Diabetes Drugs Market report delivers the clean elaborated structure of the market including each and every business-related important information of the market. The complete range of information is obtained through various sources and this obtained bulk of the information is arranged, processed, and represented by a group of specialists through the applicat...
More from
American Diabetes Journals 08/20/2019 15:00
In summary, the results of this large population-based cohort study indicate that use of SGLT2 inhibitors is not associated with an increased risk of fractures compared with use of DPP-4 inhibitors.
More from American Diabetes Journals:
FiercePharmaManufacturing 08/20/2019 10:01
AstraZeneca is still stinging after its SGLT2 diabetes drug Farxiga was waved off by the FDA in Type 1 disease.
More from FiercePharmaManufacturing:
PharmaTimes 08/20/2019 07:01
Forxiga has had a string of successes recently, as it was recommended by NICE and had its EU marketing authorisation updated earlier this month.
More from PharmaTimes:
ENDPOINTS 08/20/2019 06:52
SGLT2 makers have been vying for bigger market share by differentiating their drugs on the basis of therapeutic impact on renal impairment — but the major, most lucrative battleground is the heart.
More from ENDPOINTS:
pharmaphorum 08/20/2019 06:22
AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabetes. Farxiga is an SGLT2 class drug, which until now has b...
More from pharmaphorum:
Pharmafile 08/20/2019 06:12
New Phase 3 data has been unveiled for AstraZeneca’s Farxiga (dapagliflozin), confirming that the SGLT2 inhibitor met its primary composite endpoint when added to standard of care by achieving a "statistically-significant and clinically-meaningful reduction of cardiovascular death or the worsening of heart failure (defined as hospitalisation or an urgent heart failure visit)", compared to placebo. The data was derived from a study comprised of patients with reduced ejection fraction (HFrEF) when given standard of care treatment, including those with and without type-2 diabetes.
More from Pharmafile:
PMLiVE 08/20/2019 05:47
The phase 3 DAPA-HF trial has shown that SGLT2 inhibitor Farxiga (dapagliflozin) was able to reduce cardiovascular death or the worsening of hearty failure, compared to placebo, in heart failure patients with reduced ejection fraction (HFrEF.
More from PMLiVE:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications